Boundless Bio, Inc.
Boundless Bio (Nasdaq: BOLD) is a clinical-stage oncology company developing small-molecule therapies intended to disrupt extrachromosomal DNA (ecDNA) biology in cancers with oncogene amplification. Its proprietary Spyglass platform uses cancer models, analytical tools and genomic data to identify and validate… From the company’s description.
In fiscal 2025, Boundless Bio, Inc. reported a net loss of $58.20M. Operations used $46.66M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Boundless Bio, Inc. does
In the company’s own words
Boundless Bio (Nasdaq: BOLD) is a clinical-stage oncology company developing small-molecule therapies intended to disrupt extrachromosomal DNA (ecDNA) biology in cancers with oncogene amplification. Its proprietary Spyglass platform uses cancer models, analytical tools and genomic data to identify and validate cellular targets essential to ecDNA function. The company’s lead candidate, BBI-940, is an oral, selective degrader targeting a kinesin involved in ecDNA segregation during cell division. In February 2026, Boundless Bio began the Phase 1 KOMODO-1 trial of BBI-940 in patients with ER-positive, HER2-negative breast cancer following CDK4/6 inhibitor and endocrine therapy, and in patients with the luminal androgen receptor subtype of triple-negative breast cancer. The company had also developed BBI-355, a CHK1 inhibitor, and BBI-825, an RNR inhibitor; it discontinued enrollment in their POTENTIATE trial in January 2026 after prioritizing BBI-940. Founded in 2018, Boundless Bio has additional preclinically validated targets and retains global rights to its internally discovered programs.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- LA JOLLA, CA
- Fiscal year end
- December
- CIK
- 1782303
- SIC
- 2834
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Boundless Bio, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Boundless Bio, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Boundless Bio, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Boundless Bio, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Boundless Bio, Inc.'s last four quarterly filings that the numbers alone won't show?”